Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Pliant Therapeutics Inc's Business Segments
Pliant Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Description of Pliant Therapeutics Inc
Pliant Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of novel therapies for fibrotic diseases. Fibrosis is a complex pathological process characterized by excessive scarring and tissue damage, which can lead to organ dysfunction and failure. Pliant Therapeutics aims to address this unmet medical need by developing innovative drugs that can halt or reverse fibrosis.
The company was founded in 2016 and is headquartered in Redwood City, California. Pliant Therapeutics was formed based on groundbreaking research conducted by leading scientists in the field of fibrosis. The company's proprietary platform includes a deep understanding of the biology underlying fibrosis and a robust drug discovery engine.
One of the key strengths of Pliant Therapeutics is its team of experienced scientists and researchers. The company has assembled a multidisciplinary team with expertise in fibrotic disease biology, medicinal chemistry, drug development, and clinical research. This talented team is dedicated to identifying and advancing novel therapeutics to treat fibrosis.
Pliant Therapeutics has a diverse portfolio of drug candidates targeting various fibrotic diseases. These include idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and liver fibrosis. The company's drug candidates are designed to selectively target specific pathways involved in fibrosis, thereby addressing the underlying cause of the disease.
Central to Pliant Therapeutics' approach is the use of small molecule drugs. Small molecules have several advantages, including oral administration, excellent tissue penetration, and the ability to target specific disease pathways. The company's drug discovery process involves identifying highly selective small molecules that can modulate fibrotic pathways and conducting rigorous preclinical and clinical studies to assess their safety and efficacy.
In addition to its proprietary drug discovery efforts, Pliant Therapeutics collaborates with academic institutions and other biopharmaceutical companies through strategic partnerships. These collaborations enable the company to leverage external expertise, access novel technologies, and accelerate the development of its drug candidates.
Pliant Therapeutics has achieved significant milestones since its inception. The company has successfully raised multiple rounds of financing, securing substantial investments from leading venture capital firms and strategic partners. This financial support has enabled Pliant Therapeutics to advance its drug candidates into clinical trials and expand its research and development activities.
In summary, Pliant Therapeutics Inc is a biopharmaceutical company at the forefront of developing innovative therapies for fibrotic diseases. With its deep understanding of fibrosis biology, experienced team, and diverse portfolio of drug candidates, the company is well-positioned to address the unmet medical needs of patients suffering from debilitating fibrotic diseases.
The company was founded in 2016 and is headquartered in Redwood City, California. Pliant Therapeutics was formed based on groundbreaking research conducted by leading scientists in the field of fibrosis. The company's proprietary platform includes a deep understanding of the biology underlying fibrosis and a robust drug discovery engine.
One of the key strengths of Pliant Therapeutics is its team of experienced scientists and researchers. The company has assembled a multidisciplinary team with expertise in fibrotic disease biology, medicinal chemistry, drug development, and clinical research. This talented team is dedicated to identifying and advancing novel therapeutics to treat fibrosis.
Pliant Therapeutics has a diverse portfolio of drug candidates targeting various fibrotic diseases. These include idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and liver fibrosis. The company's drug candidates are designed to selectively target specific pathways involved in fibrosis, thereby addressing the underlying cause of the disease.
Central to Pliant Therapeutics' approach is the use of small molecule drugs. Small molecules have several advantages, including oral administration, excellent tissue penetration, and the ability to target specific disease pathways. The company's drug discovery process involves identifying highly selective small molecules that can modulate fibrotic pathways and conducting rigorous preclinical and clinical studies to assess their safety and efficacy.
In addition to its proprietary drug discovery efforts, Pliant Therapeutics collaborates with academic institutions and other biopharmaceutical companies through strategic partnerships. These collaborations enable the company to leverage external expertise, access novel technologies, and accelerate the development of its drug candidates.
Pliant Therapeutics has achieved significant milestones since its inception. The company has successfully raised multiple rounds of financing, securing substantial investments from leading venture capital firms and strategic partners. This financial support has enabled Pliant Therapeutics to advance its drug candidates into clinical trials and expand its research and development activities.
In summary, Pliant Therapeutics Inc is a biopharmaceutical company at the forefront of developing innovative therapies for fibrotic diseases. With its deep understanding of fibrosis biology, experienced team, and diverse portfolio of drug candidates, the company is well-positioned to address the unmet medical needs of patients suffering from debilitating fibrotic diseases.
Pliant Therapeutics Inc. is a biopharmaceutical company focused on advancing innovative therapies for patients with fibrotic diseases. The company leverages its expertise in drug discovery and development to tackle complex conditions resulting from abnormal tissue scarring and excessive collagen deposition.
Segments
1. Fibrotic Diseases: Pliant primarily focuses on developing treatments for various fibrotic diseases that can affect multiple organs, including the lungs, liver, and kidneys. The company is particularly focused on targeting mechanisms that modulate the transformation of fibroblasts into myofibroblasts, the cells responsible for excessive fibrosis.
2. Drug Development: Pliant is engaged in the research and development of small molecules that can inhibit specific signaling pathways involved in fibrosis. The company’s pipeline includes therapies designed to target specific fibrotic pathways at various stages of clinical development.
Products
Pliant Therapeutics has several key product candidates in its portfolio, which aim to address different types of fibrotic diseases:
1. Bezacostat (PLI-101): This is one of the leading candidates in Pliants pipeline focused on treating liver fibrosis. It seeks to reduce liver scarring in conditions such as nonalcoholic steatohepatitis (NASH) and potentially, primary sclerosing cholangitis (PSC). The drug works by modulating the immune response and fibrosis-related pathways, ultimately aiming to reverse fibrosis progression.
2. PLI-102: This product candidate is targeting idiopathic pulmonary fibrosis (IPF). By inhibiting the activation of myofibroblasts and reducing collagen deposition in lung tissue, PLI-102 aims to improve lung function and quality of life for patients with this progressive disease.
3. PLI-103: Focused on renal fibrosis, PLI-103 is developed to address kidney ailments, potentially benefiting patients with diabetic nephropathy and other conditions characterized by kidney scarring.
Services
While Pliant is mainly a product-focused biopharmaceutical company, it engages in several ancillary services that complement its core mission:
1. Clinical Trials and Research: Pliant conducts extensive clinical trials to evaluate the efficacy and safety of its drug candidates. This includes multi-phase trials that not only assess drug performance but also gather data on patient populations and disease progression.
2. Collaborations and Partnerships: Pliant engages with academic institutions, healthcare providers, and other pharmaceutical companies for collaborative research in fibrosis and drug development. These partnerships enhance knowledge sharing and accelerate the discovery of therapeutic avenues.
3. Regulatory Affairs: The company invests in navigating regulatory pathways to secure approvals for its investigational therapies. This includes interactions with regulatory bodies to ensure compliance and address safety or efficacy concerns.
4. Patient Education and Advocacy: Pliant is committed to educating patients and healthcare practitioners about the impact of fibrotic diseases, including the importance of early diagnosis and treatment options available.
5. Global Outreach: As part of its service offerings, Pliant explores opportunities to reach global markets, recognizing the global burden of fibrotic diseases and the need for accessible therapies.
In summary, Pliant Therapeutics Inc. is deeply invested in providing transformative therapies for patients suffering from fibrotic diseases through innovative drug development and supportive services aimed at research and education. Its portfolio reflects a strong commitment to addressing critical unmet needs in the field of fibrology.
Segments
1. Fibrotic Diseases: Pliant primarily focuses on developing treatments for various fibrotic diseases that can affect multiple organs, including the lungs, liver, and kidneys. The company is particularly focused on targeting mechanisms that modulate the transformation of fibroblasts into myofibroblasts, the cells responsible for excessive fibrosis.
2. Drug Development: Pliant is engaged in the research and development of small molecules that can inhibit specific signaling pathways involved in fibrosis. The company’s pipeline includes therapies designed to target specific fibrotic pathways at various stages of clinical development.
Products
Pliant Therapeutics has several key product candidates in its portfolio, which aim to address different types of fibrotic diseases:
1. Bezacostat (PLI-101): This is one of the leading candidates in Pliants pipeline focused on treating liver fibrosis. It seeks to reduce liver scarring in conditions such as nonalcoholic steatohepatitis (NASH) and potentially, primary sclerosing cholangitis (PSC). The drug works by modulating the immune response and fibrosis-related pathways, ultimately aiming to reverse fibrosis progression.
2. PLI-102: This product candidate is targeting idiopathic pulmonary fibrosis (IPF). By inhibiting the activation of myofibroblasts and reducing collagen deposition in lung tissue, PLI-102 aims to improve lung function and quality of life for patients with this progressive disease.
3. PLI-103: Focused on renal fibrosis, PLI-103 is developed to address kidney ailments, potentially benefiting patients with diabetic nephropathy and other conditions characterized by kidney scarring.
Services
While Pliant is mainly a product-focused biopharmaceutical company, it engages in several ancillary services that complement its core mission:
1. Clinical Trials and Research: Pliant conducts extensive clinical trials to evaluate the efficacy and safety of its drug candidates. This includes multi-phase trials that not only assess drug performance but also gather data on patient populations and disease progression.
2. Collaborations and Partnerships: Pliant engages with academic institutions, healthcare providers, and other pharmaceutical companies for collaborative research in fibrosis and drug development. These partnerships enhance knowledge sharing and accelerate the discovery of therapeutic avenues.
3. Regulatory Affairs: The company invests in navigating regulatory pathways to secure approvals for its investigational therapies. This includes interactions with regulatory bodies to ensure compliance and address safety or efficacy concerns.
4. Patient Education and Advocacy: Pliant is committed to educating patients and healthcare practitioners about the impact of fibrotic diseases, including the importance of early diagnosis and treatment options available.
5. Global Outreach: As part of its service offerings, Pliant explores opportunities to reach global markets, recognizing the global burden of fibrotic diseases and the need for accessible therapies.
In summary, Pliant Therapeutics Inc. is deeply invested in providing transformative therapies for patients suffering from fibrotic diseases through innovative drug development and supportive services aimed at research and education. Its portfolio reflects a strong commitment to addressing critical unmet needs in the field of fibrology.